Independent Conference Coverage from the CHEST 2019 Annual Meeting*
Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.


Current Perspective on Antifibrotic Therapy for Patients with IPF

Launched: October 25, 2019

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases (The INBUILD Trial)
Launched: October 25, 2019

 


Goals of Care Across the Disease Continuum in IPF
Launched: October 25, 2019

Emerging Diagnostic Approaches to Patients with ILD
Launched: October 25, 2019

 


Pirfenidone in Patients with Unclassifiable Interstitial Lung Disease
Launched: October 25, 2019


Considerations for Geriatric ILD Patients

Launched: October 25, 2019

 



Nintedanib for Patients with Systemic Sclerosis-Related Interstitial Lung Disease

Launched: October 25, 2019

Inhaled NO in Patients at Risk for Pulmonary Hypertension Associated with Pulmonary Fibrosis
Launched: October 25, 2019

 


Clinical Pearls from New Orleans 2019
Launched: October 24, 2019


*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings of the 2019 CHEST Annual Meeting.